This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

MLex Comment: Pfizer, Wyeth deal may not cause sizeable antitrust concerns

By Dafydd Nelson ( February 10, 2009, 15:42 GMT | Comment) -- Pfizer’s announcement that it will acquire rival drug-maker Wyeth appears unlikely, at first glance, to pose the European Commission any sizeable antitrust concerns meaning that a Phase I clearance, possibly with some remedies, is the most probable outcome. Nevertheless, some overlaps are inevitable in a deal involving two large pharmaceuticals companies; for example, both are active in the production of popular prescription antidepressant drugs.Pfizer’s announcement that it will acquire rival drug-maker Wyeth appears unlikely, at first glance, to pose the European Commission any sizeable antitrust concerns. The companies’ portfolios seem largely complementary meaning that a Phase I clearance, possibly with some remedies, is the most probable outcome....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login